ストックスクリーナーアプリを入手
31.38
4.42%
-1.45
前日終値:
$32.83
開ける：
$32.83
24時間の取引高:
611.83K
Relative Volume:
0.88
時価総額：
$1.95B
収益：
$32.08M
当期純損益:
$-169.77M
株価収益率:
-11.04
EPS:
-2.8418
ネットキャッシュフロー:
$-147.70M
1週間 パフォーマンス:
-4.04%
1か月 パフォーマンス:
+10.18%
6か月 パフォーマンス:
-4.47%
1年 パフォーマンス:
+160.63%
1日の値動き範囲:
$30.07
$33.02
1週間の範囲:
$30.07
$33.72
52週間の値動き範囲:
$11.66
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
31.38 | 1.95B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-05 | 開始されました | Guggenheim | Buy |
| 2026-01-05 | 再開されました | Chardan Capital Markets | Buy |
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
(STOK) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT) - TradingView
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows - ad-hoc-news.de
Stoke Therapeutics holds the focus. Investors await the next evidence - ad-hoc-news.de
Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan
Stoke Therapeutics faces earnings test after revenue miss By Investing.com - Investing.com Nigeria
Stoke Therapeutics (STOK) Receives a Buy from Jefferies - The Globe and Mail
STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales - Stock Titan
Stoke Therapeutics (STOK) Edges Lower as Stock Consolidates Near Key LevelsETF Flow - dars.gov.et
Responsive Playbooks and the STOK Inflection - Stock Traders Daily
Stoke completes phase 3 enrollment for Dravet syndrome drug - Investing.com UK
Stoke completes Phase 3 enrollment for Dravet drug study - grafa.com
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome - BioSpace
Stoke Therapeutics Advances Zorevunersen in Dravet Syndrome Stud - GuruFocus
Stoke Therapeutics (STOK) Advances Phase 3 Study and NDA Plans - GuruFocus
Stoke Therapeutics Completes Enrollment in Phase 3 Dravet Trial - TipRanks
Stoke completes phase 3 enrollment for Dravet syndrome drug By Investing.com - Investing.com Canada
Stoke CEO Ian Smith to speak April 14 at Needham healthcare event - Stock Titan
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027 - TradingView
Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA - Stock Titan
Dravet Syndrome Foundation (DSF) Announces 2026 Community Award Winners - EIN Presswire
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell 3000E Index - marketscreener.com
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index - marketscreener.com
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)? - simplywall.st
Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
STOK Forecast — Price Target — Prediction for 2027 - TradingView
Stoke Therapeutics, Inc. Actuals & Estimates (NASDAQ:STOK) - TradingView
0GT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Enterprise value to EBITDA forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Enterprise value to EBITDA forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Price to book forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics (STOK) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Stoke Therapeutics StockLong-term strategy and genetic medicine pipeline - ad-hoc-news.de
Understanding the Setup: (STOK) and Scalable Risk - Stock Traders Daily
Stoke Therapeutics general counsel sells $43,637 in common stock By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel sells $43,637 in common stock - Investing.com UK
Insider Sell Alert: Jonathan Allan Sells Shares of Stoke Therape - GuruFocus
Stoke Therapeutics (STOK) legal chief sells 1,457 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):